Upper airway considerations in hereditary angioedema

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 1, 2010, Pages 20-25

  Papadopoulou Alataki, Efimia ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

C1 inhibitor; Hereditary angioedema; Swelling; Upper airway

Indexed keywords

AMINOCAPROIC ACID; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; IMMUNOLOGIC AGENT; OXANDROLONE; RHUCIN; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASPHYXIA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPHAGIA; DYSPHONIA; EMERGENCY TREATMENT; ENDOTRACHEAL INTUBATION; FACE EDEMA; FOREIGN BODY; GASTROINTESTINAL SYMPTOM; HOARSENESS; HUMAN; LARYNX EDEMA; LIVER TOXICITY; LOCAL DISCOMFORT; LOW DRUG DOSE; MORBIDITY; MORTALITY; ONSET AGE; ORAL SURGERY; OXYGEN SATURATION; PARTIAL THROMBOPLASTIN TIME; PATIENT EDUCATION; PERITONSILLAR ABSCESS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INTUBATION; REVIEW; SIDE EFFECT; STRIDOR; TONGUE SWELLING; TONSILLITIS; TOOTH EXTRACTION; UPPER RESPIRATORY TRACT OBSTRUCTION; VIRILIZATION;

ANGIOEDEMAS, HEREDITARY; ASPHYXIA; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 11; COMPLEMENT C1 INHIBITOR PROTEIN; DIAGNOSIS, DIFFERENTIAL; EDEMA; HUMANS; INCIDENCE; RESPIRATORY SYSTEM;

EID: 76149101260     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328334f629     Document Type: Review

References (37)

1. Temino VM, Peebles RS. The spectrum and treatment of angioedema. Am J Med 2008; 121:282-286.
2. Cugno M, Zanichelli A, Bellatorre AG, et al. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64:254-257.
3. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15:69-78.
4. Davis AE. Hereditary angioedema: a current state of the art review. III: mechanisms of hereditary angioedema. Ann Allerg Asthma Im 2008; 100:S7-S12.
5. Bernstein IL. Hereditary angioedema: a current state-of-the-art review. II: historical perspective of non-histamine-induced angioedema. Ann Allerg Asthma Im 2008; 100:S2-S16.
6. Reshef A, Leibovich I, Goren A. Hereditary angioedema: new hopes for an orphan disease. Allergy Clin Immunol 2008; 10:850-855.
7. Wagenaar-Bos IGA, Drouet C, Aygoren-Pursyn E, et al. Functional C1- inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008; 338:14-20.
8. Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missence mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124:129-134.
9. HAEdb. C1 Inhibitor gene mutation database. http://haeenzimhu/2008.
10. Pappalardo E, Caccia S, Suffritti C, et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema; functional and structural correlates. Mol Immunol 2008; 45:3536-3544.
11. Buyukozturk S, Eroglu BK, Gelincik A, et al. A Turkish family with a novel mutation in the promoter region of the C1 inhibitor gene. J Allergy Clin Immunol 2009; 123:962-964.
12. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359:1027-1036.
13. Speletas M, Boukas K, Papadopoulou-Alataki E, et al. Hereditary angioedema in Greek families due to novel and recurrent mutations. Hum Immunol 2009; 70: 925-929.
14. Zuraw BL. Hereditary angioedema: a current state-of-the-art review. IV: shortand long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Astma Im 2008; 100:S13-S18.
15. Papadopoulou-Alataki E, Foerster T, Antari V, et al. Molecular diagnosis and management of hereditary angioedema in a Greek family. Int Arch Allergy Immunol 2008; 147:166-170.
16. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120:713-722.
17. Rice S, Cochrane TJ, Millwaters M, Ali NT. Emergency management of upper airway angio-oedema after routine dental extraction in a patient with C1 esterase deficiency. Brit J Oral Max Surg 2008; 46:394-396.
18. Nagler R, Muska E, Laster Z. Induced acute hereditary angioedema: a lifethreatening condition. J Oral Maxillofac Surg 2008; 66:1287-1289.
19. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs and course. Am J Med 2006; 119:267-274.
20. Bork K, Staubach P, Hard J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angioedema. Allergy 2008; 63:751-757.
21. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceeding of the third C1-esterase inhibitor deficiency. Workshop and beyond. J Allergy Clin Immunol 2004; 114:S51-S139.
22. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-ofthe- art review, VII: Canadian Hungarian 2007 international consencus algorithm for the diagnosis, therapy and management of hereditary angioedema. Ann Allergy Asthma Im 2008; 100:S30-S40.
23. Epstein TG, Berstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs 2008; 68:2562-2573.
24. Cocchio C, Marzella N. Cinryze, a human plasma-derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. Drug Forecast 2009; 34:293-296.
25. Frank MM. Hereditary angioedema: a current state-of-the-art review. VI: novel therapies for hereditary angioedema. Ann Allergy Asthma Im 2008; 100:S23-S29.
26. Berstein JA. Hereditary angioedema: a current state-of-the-art review. VIII: current status of emerging therapies. Ann Allergy Asthma Im 2008; 100:S41-S46.
27. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120:941-947.
28. Cicardi M, Zingale L, Zanichelli A, Lambertenghi Deliliers D. Established and new treatments for hereditary angioedema: an update. Mol Immunol 2007; 44:3858-3861.
29. Bygum A, Andersen KE, Mikkelsen CS. Self administration of intravenous C1- inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19:147-151.
30. Prematta MJ, Prematta T, Craig TJ. Treatment of hereditary angioedema with plasma derived C1 inhibitor. Therapeutics and Clinical Risk Management 2008; 4:975-982.
31. FrankMM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008; 121:272-280.
32. Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trail of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120:416-422.
33. Davis AE. New treatments addressing the pathophysiology of hereditary angioedema. Clinical and Molecular Allergy 2008; 6:1-7.
34. Bas M, Bier H, Greve J, et al. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006; 61:1490-1492.
35. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-ofthe- art review. V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Astma Im 2008; 100:S19-S212.
36. Levi M, Choi G, Picavet C, Hack CE. Self administration of C1-Inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-Inhibitor deficiency. J Allergy Clin Immun 2006; 117:904-908.
37. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009; 49:1987-1995.